A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ...

In addition to its quantum readiness and multi-cloud security updates, PAN-OS 12.1 Orion expands Palo Alto Networks’ ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III ...

Exelixis ’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...

Added to previous studies, "these findings provide our strongest evidence that ovarian cancer prevention must extend beyond OS [opportunistic salpingectomy] to include genetic testing and ...

POCO has launched a new smartphone — the POCO M7 Plus 5G — in India on Wednesday, August 13 under Rs 13,000. The device comes ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Q2 2025 Earnings Call Transcript August 9, 2025 Operator: Greetings, and welcome to the Immunocore conference call and ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

Data suggest that “venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population,” the researchers wrote.

Feature Britain's Ordnance Survey (OS), founded in 1791, is interloping in the digital age. Minecraft, AR gaming, and EV ...

When you buy through links on our articles, Future and its syndication partners may earn a commission.